Health
FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19 – News-Medical.Net
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment…
-
Noosa News20 hours agoYoung voices shape Sunshine Coast’s future
-
Business19 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News17 hours agoStar Entertainment signs $300m lifeline deal with US gaming giant Bally’s
-
Noosa News19 hours agoQueensland government to review greenhouse gas emission reduction targets